Why Amgen Stock Vaulted Higher Today

What happened

Shares of Amgen (NASDAQ: AMGN) were vaulting 5.9% higher as of 3:21 p.m. EDT on Tuesday. The nice jump came after the announcement that the stock would be added to the Dow Jones Industrial Average, replacing Pfizer

So what

There are two main reasons why investors cheered today's news for Amgen. One was more symbolic, while the other was quite practical.

Dow in green letters in a green circle with three small green arrows pointing up

Image source: Getty Images.

The addition of Amgen to the Dow Jones index was symbolically a significant kudo for the company. Amgen will become the first biotech stock to ever be included in the prestigious index. Becoming part of the Dow Jones Industrial Average reflects Amgen's accomplishments in establishing itself as a major player in the healthcare sector.

There's also a practical and tangible benefit from Amgen's inclusion in the Dow. Several mutual funds and exchange-traded funds (ETFs) track the Dow Jones Industrial Average. These funds will buy shares of Amgen, potentially driving the stock higher in the process.

Now what

Amgen won't officially become part of the Dow Jones index until Aug. 31, 2020. While the stock's addition to the index will provide a temporary boost, the more important thing to focus on will continue to be Amgen's pipeline progress. The biotech expects to announce key results from late-stage studies for two candidates later this year, tezepelumab in treating asthma and omecamtiv mecarbil in treating heart failure.

10 stocks we like better than Amgen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amgen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Keith Speights owns shares of Pfizer. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.